Advertisement

Patient Safety & Outcomes

A study was conducted in Nova Scotia to assess the risks associated with aprotinin, which the authors hypothesized is associated with higher risk of adverse outcomes than tranexamic acid, according to MDLinx.

Advertisement
Advertisement